SBIR/STTR Research Award
TAS::75 0849::TAS SBIR TOPIC 277 - PHASE I SNAPMAPTM: A FUNCTIONAL COMPANION DIAGNOSTIC TEST
Award amount
$192,786Program and phase
SBIR · Phase IAward year
2011Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Biomarker Strategies, LLC
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- MMRCBR1M7WN5
- Solicitation number
- Not reported
- Topic code
- NCI
Research abstract
Most of the currently utilized predictive biomarkers for therapeutic decision-making provide information about the presence or absence of the drug target, but reveal little about the functional circuitry of the signaling network that the drug must also impact. Ex vivo biomarkers are dynamic molecular markers evoked from living tumor cells after removal from the patient. Such ex vivo biomarkers provide valuable mechanistic information that may facilitate drug development and guide the clinical selection of targeted therapeutics. We propose to develop a companion diagnostic test, named SnapMap, for drugs targeting the ErbB signal transduction network. This test will utilize tumor biopsy samples processed on the SnapPath tumor processing system to evoke ex vivo biomarkers from live tumor samples.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- SBIR TOPIC 354: A NOVEL PREDICTIVE TEST FOR RESPONSE TO COMBINATION IMMUNOTHERAPIES FOR PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC)
- PathMAP NSCLC: A functional companion diagnostic test to predict optimal therapy for patients with non-small cell lung cancer.
- Development of a companion diagnostic to predict response to cetuximab in patients with head and neck squamous cell carcinoma
- IGF OT IGF SBIR PHASE I TOPIC A NOVEL PREDICTIVE TEST FOR RESPONSE TO IMMUNOTHERAPIES FOR PATIENTS WITH NON SMALL CELL LUNG CANCER POP
- PathMAP NSCLC: A functional companion diagnostic test to predict optimal therapy for patients with non-small cell lung cancer.
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Mini-reflectance confocal microscope (Mini-RCM) for aiding skin cancer diagnosis and treatment
- Development of small molecule therapeutics targeting AR-V7 for prostate cancer
- Decentralized Clinical Trial of Effectiveness of EnergyPoints App to Guide Acupressure Use for Fatigue and Sleep Disturbances in Cancer Survivors
- Optimized targeted radiotherapy of pancreatic cancer
- Adaptive imaging for pioneering multiplexed spatial profiling of tumors and tissues for cancer research and diagnosis
Research funding history
9 SBIR/STTR records share this UEI (2009–2019). Reported award amounts total $7,286,589. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services